PROCEPT BIOROBOTICS AB2000 Aquabeam Aquablation Therapy Robotic

( Brand: Procept Biorobotics ), ( Manufacturer Part Number: AB2000 ), ( Model: AQUABEAM )

Review PROCEPT BIOROBOTICS Aquabeam Aquablation Therapy Robotic System

The Procept Biorobotics AB2000 Aquabeam Aquablation Therapy Robotic System is a state-of-the-art medical device designed for the minimally invasive treatment of various urological conditions, particularly benign prostatic hyperplasia (BPH). This advanced robotic system integrates precise waterjet technology with the latest in robotic automation to deliver accurate and consistent results.

The AB2000 system consists of a console, a patient-side cart, and a handheld Aquabeam handpiece. The console houses the system's computer and controls, allowing the urologist to visualize the treatment area in real-time through the integrated imaging system. The patient-side cart is equipped with a flexible cystoscope and hydrodistention capabilities, ensuring a thorough examination of the urinary tract.

The handheld Aquabeam handpiece is the heart of the system, delivering the Aquablation therapy. This innovative technology utilizes a high-pressure, laminar waterjet to precisely remove obstructive prostate tissue while preserving the surrounding healthy tissue. The waterjet's stream is controlled by the urologist via the console, providing unparalleled precision and accuracy.

The AB2000 system offers several advantages over traditional BPH treatment methods. It is a minimally invasive procedure, meaning that patients typically experience less pain, fewer complications, and a shorter recovery time. Moreover, the waterjet technology ensures that healthy tissue is preserved, reducing the risk of side effects such as incontinence or sexual dysfunction.

The Procept Biorobotics AB2000 Aquabeam Aquablation Therapy Robotic System is designed to improve the quality of life for patients suffering from BPH symptoms. It offers urologists a precise, efficient, and effective solution for treating this common condition, making it an essential tool in modern urology practices.

1. Precision: The AB2000 system utilizes real-time ultrasound imaging and robotic technology to deliver highly precise and consistent treatments for benign prostatic hyperplasia (BPH).

2. Minimally Invasive: Aquablation therapy, performed with the AB2000 system, is a minimally invasive alternative to traditional surgical procedures for BPH, such as transurethral resection of the prostate (TURP).

3. Faster Recovery: Compared to TURP, patients who undergo Aquablation therapy with the AB2000 system typically experience a faster recovery time. This is due to the absence of thermal damage and the smaller incisions required for the procedure.

4. Reduced Risk of Side Effects: The risk of side effects, such as urinary incontinence and sexual dysfunction, is generally lower with Aquablation therapy compared to TURP.

5. Customizable: The AB2000 system allows for customized treatments based on the unique anatomy of each patient, ensuring optimal results.

1. High Cost: The AB2000 system is a significant investment for healthcare providers, as it is a sophisticated and advanced medical device. The cost of the system, along with ongoing maintenance and training, may be a barrier to adoption for some practices.

2. Limited Indications: Currently, the AB2000 system is only approved for the treatment of BPH. While this is a common condition, it may limit the potential market for the device in comparison to more versatile systems.

3. Learning Curve: As with any new medical technology, there is a learning curve associated with using the AB2000 system effectively. Healthcare providers may need to invest time and resources in training their staff to ensure optimal patient outcomes.

The Procept Biorobotics AB2000 Aquabeam Aquablation Therapy Robotic offers numerous advantages for the treatment of benign prostatic hyperplasia, including precision, minimally invasive procedure, faster recovery, and reduced risk of side effects. However, the high cost and limited indications may be a barrier to adoption for some healthcare providers. Ultimately, the decision to invest in the AB2000 system should be based on an careful analysis of the potential benefits and costs for your practice and patient population.

If your practice treats a significant number of patients with benign prostatic hyperplasia and you are looking for a minimally invasive, precise, and effective treatment option, the Procept Biorobotics AB2000 Aquabeam Aquablation Therapy Robotic is an excellent choice. However, you should carefully consider the upfront and ongoing costs, as well as the learning curve associated with the device, before making a final decision. It may be helpful to consult with other healthcare providers who have experience using the AB2000 system to gain a better understanding of the benefits and challenges.

Details:

Used but in good condition as shown. Only includes what is shown in the pictures, no other parts or accessories included. Item#126010L. No TRUS Probe or Hand piece included.

part #: ab2000 prices

• $189.81-$3800.00

specifications labequipi:

• brand: Procept Biorobotics
• mpn: Ab2000
• model: Aquabeam

seller labequipi:

• # reviews: 11693
• city: Sioux Falls, South Dakota
• rating: 99.2%

payments labequipi:

• wallet: Apple-pay
• credit card: Diners-club
• other

general labequipi:

• condition: Used
• Healthcare, Lab Dental > Medical Lab Equipment, Devices > Other Medical Lab Equipment

offer labequipi:

• sold: 0
• options: Ship-to-home
• quantity: 1
• availability: In Stock
• best offers: True
• started: January 16, 2026

shipping labequipi:

• type: Fixed
• cost: $570.00
• class: Freight
• service: Flat Rate Freight

returns labequipi:

• policy: No Returns

Procept Biorobotics AB2000 Is Similar To:

• Procept Biorobotics P4226 Pwr-tio-to-tmon-molded Cable Rev 01 (47.3% similar) Fast shipping. Procept Biorobotics P4226 per-tio-to-Timon-molded cable rev 01, excess inventory from local company. Expedited shipping can be arranged upon request for a nominal charge...(May 23rd, 2025)